# Retatrutide References: Primary Citations from the Published Trial Record

> Full reference list for the retatrutide research digest. Phase 1b through Phase 3 TRANSCEND-T2D-1, MASLD substudy, mechanism studies, and discontinuation literature. DOIs and PubMed links.

Every claim on this site traces to a numbered entry below. DOI and PubMed links throughout.

## All citations

The following 15 citations cover every numbered reference used across all pages of this site. See [Retatrutide references](/references) for the complete list.

## References

[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
[2] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/
[3] Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[4] Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. https://pubmed.ncbi.nlm.nih.gov/36354040/
[5] Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
[6] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[7] et al. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption. J Clin Med. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12155999/
[8] Melson E, et al. What is the pipeline for future medications for obesity? International Journal of Obesity. 2025;49(3):433-451. https://doi.org/10.1038/s41366-024-01473-y
[9] Caruso I, et al. Incretin-based therapies for the treatment of obesity-related diseases. npj metabolic health and disease. 2024;2(1):31. https://doi.org/10.1038/s44324-024-00030-5
[10] Deravi M, et al. The 'Weight' for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. Journal of Pharmacy Technology. 2024;40(6):300-305. https://doi.org/10.1177/87551225241285326
[11] Kusminski CM, et al. Transforming obesity: The advancement of multi-receptor drugs. Cell. 2024;187(15):3829-3853. https://doi.org/10.1016/j.cell.2024.06.003
[12] Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. https://doi.org/10.1016/S0140-6736(26)00967-0
[13] Lempesis IG, et al. Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. Metabolism Open. 2026. https://doi.org/10.1016/j.metop.2026.100463
[14] et al. Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, and the Path Forward. Cureus. 2026. https://pubmed.ncbi.nlm.nih.gov/41909366/
[15] Elmendorf AJ, et al. IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. Pharmacological Research. 2026. https://doi.org/10.1016/j.phrs.2025.108077

---

A risograph broadside reading of the retatrutide Phase 2 and Phase 3 trial record — discontinuation, durability, and the stopping question set down precisely and cited to source, with no clinic and no prescription behind the charcoal stock.